Roman Aboute

Family Cycling and Football. #SS9 Rapha addict Somewhere on my S Works. #irons

[The Long Investor @TheLongInvest]

Like, share and follow this tweet and I’ll give 5 Yearly Memberships away for free in 24hrs.

[Investseekers @investseekers]

$NVO is expanding its digital distribution in Mexico.

Novo Nordisk has launched an official store on $MELI , giving patients a verified online channel to purchase prescription medicines including Wegovy, Ozempic, Rybelsus, and Saxenda.

The initiative aims to improve access to authentic medicines while helping combat the sale of counterfeit and stolen products through unauthorized channels.

Mercado Libre will provide its logistics network, licensed pharmaceutical delivery services, and payment platform, while Novo emphasized that all products require a valid prescription and should be used under medical supervision.

Link: https://t.co/RIO4rNsqed

#stocks #Investing

[Gorilla Technology @GorillaTechGrp]

Gorilla Technology has raised its Q2 2026 revenue outlook to at least US$44 million, reflecting continued contract wins and accelerating demand for AI infrastructure.

This outlook is above current external market estimates of approximately US$33.9 million and underscores Gorilla's ability to convert signed commercial commitments into recognized revenue.

Key highlights:

✅ Q2 2026 revenue outlook raised to at least US$44 million
✅ More than 55% sequential growth versus Q1 2026
✅ More than 100% year-over-year growth versus Q2 2025
✅ Driven by strong contract execution and accelerating AI infrastructure demand

The Company hopes to provide an updated outlook for 2026 when it reports its Q2 2026 and first-half 2026 financial results.

Read the Press Release Here: https://t.co/oxsJIhRobm

#GorillaTechnology #GRRR $GRRR #AI #ArtificialIntelligence #AIInfrastructure #DataCenters #DigitalTransformation #NASDAQ #Growth

[The Long Investor @TheLongInvest]

GM

$ASTS to $150
$ZETA to $45
$DCTH to $34
$GRRR to $44
$HIMS to $55
$OSCR to $45

[Investseekers @investseekers]

$NVO

Oral Wegovy appears set to launch in the UK on July 6.

Chemist4U now states that pre-orders will be shipped once stock arrives on July 6, suggesting patients could soon get access to Novo Nordisk's once-daily obesity pill.

The UK is the first European country to approve Oral Wegovy, and if demand matches the strong interest seen before launch, it could become another important milestone for Novo

#stocks #Investing

[Roman Aboute @Pac2sales]

@TheLongInvest If you got riches you got bitches #NVO #ADUR ooo them bitches

[Roman Aboute @Pac2sales]

@InvestsDad I’m , average $45. Company buybacks going on. Good dividend and looking like it’s starting to perk up #$NVO

[The Long Investor @TheLongInvest]

Just remember

You and the market HATE $NVO and it's going to zero

Terrible position

like so bad.

[Roman Aboute @Pac2sales]

@investseekers Always nice to hear more positive news on NVO. Retail may and I say may wake up to that 10x to 40x Lilly stat. Whatever happens I can only see the $NVO share price going up 🙏

[Roman Aboute @Pac2sales]

@ResearchPulse1 That is brilliant

[Jan @janthecurious1]

$NVO is positioning for its next major growth case: China 🇨🇳

CEO Mike Doustdar and Chairman Lars Rebien Sørensen are in China this week - a strong signal of the market’s strategic importance.

- 11 million patients in China are already treated with Novo Nordisk medicines.

- 150 million live with diabetes.

- 230 million live with obesity.

With a potential launch of oral Wegovy, China could become Novo’s next major growth engine.

I still believe $NVO can reach stock price 500 before year-end.

I also expect Chinese approval of the Wegovy pill to come relatively fast after filing - potentially within months.

Chinese regulators are already familiar with semaglutide from existing treatments.

The market is still mostly focused on the US.

In a few months, the markets in the UK and EU will be up and running.

[Roman Aboute @Pac2sales]

@Aktieland @NikolajWinther6 And a buyback in place the current price is a no brainer #NVO

[Roman Aboute @Pac2sales]

@TheLongInvest Purchased @$16 Yah! $HIMS #patreon

[Roman Aboute @Pac2sales]

Anyone else taking notice of the expanding buybacks. This signals confidence in the company’s long term prospects
$NVO

[The Long Investor @TheLongInvest]

Who's going to get to $40 first?

$OSCR
$HIMS

[Laser-Cut @RockBolig]

$NVO
$LLY

Zenagamtide just delivered what is truly the most impressive diabetes data ever.

14.6% weight loss in type 2 diabetes after only 36 weeks, no weight-loss plateau observed, and 89% of patients achieved HbA1c below 7%.

Compared with Eli Lilly these results look highly competitive despite much shorter exposure to the highest dose.

If phase 3 confirms these findings, Novo may have a therapy that surpasses Lilly’s current offerings in both glucose control and weight reduction.

The obesity and diabetes race is far from over.

Let’s go $NVO 💪

[Roman Aboute @Pac2sales]

@TheLongInvest Cheers cap trimmed some -$NVO and I’m in $RR. Nice work again

[Roman Aboute @Pac2sales]

@TheLongInvest You certainly do my friend 💪

[Roman Aboute @Pac2sales]

@TheLongInvest $GRAB

[Roman Aboute @Pac2sales]

@TheValueTrade Name a bank that isn’t a joke